Equities

Exact Sciences Corp

Exact Sciences Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)50.16
  • Today's Change-1.17 / -2.28%
  • Shares traded1.06k
  • 1 Year change-16.06%
  • Beta1.2115
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Company’s products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Company’s flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.

  • Revenue in USD (TTM)2.69bn
  • Net income in USD-214.04m
  • Incorporated1995
  • Employees6.50k
  • Location
    Exact Sciences Corp5505 Endeavor LaneMADISON 53719United StatesUSA
  • Phone+1 (608) 284-5700
  • Fax+1 (608) 284-5701
  • Websitehttps://www.exactsciences.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Blueprint Medicines Corp434.41m-128.05m6.14bn638.00--19.58--14.13-2.11-2.116.924.930.37690.89548.11663,227.50-11.11-29.92-13.84-34.0697.01---29.48-116.653.27-10.800.5525--22.2241.149.06--4.85--
Cytokinetics, Inc.3.22m-576.40m6.61bn423.00------2,053.83-5.39-5.390.0301-0.1180.003--2.357,609.93-52.96-43.14-57.95-47.22-----17,906.24-540.47---14.271.02---92.04-24.89-35.30--9.76--
Viking Therapeutics Inc0.00-99.15m6.75bn33.00--7.41-----0.937-0.9370.008.180.00----0.00-15.02-21.91-15.47-23.04------------0.00-------24.73------
Madrigal Pharmaceuticals Inc76.81m-518.67m7.39bn376.00--9.51--96.27-25.07-25.073.7135.640.1172----204,289.90-79.11-62.09-100.35-74.8196.37---675.24--5.93--0.1309-------26.50--132.01--
Legend Biotech Corp (ADR)455.99m-285.01m7.40bn2.20k--6.35--16.24-1.57-1.572.516.330.244610.6332.42253,328.30-15.29-37.71-17.63-47.1960.28---62.50-286.514.78--0.2263--143.7042.15-16.11--1.57--
Exact Sciences Corp2.69bn-214.04m9.28bn6.50k--2.895,092.393.45-1.17-1.1714.7017.350.40895.4011.60414,204.30-3.25-9.71-3.58-10.6072.9674.10-7.95-28.211.93--0.4459--19.9340.6367.26---3.71--
Revolution Medicines Inc742.00k-567.06m9.98bn490.00--6.35--13,450.75-3.59-3.590.00479.340.0005--4.801,962.96-41.28-29.76-44.46-32.59-----76,423.31-606.93----0.00---67.27-10.50-75.46--38.82--
Exelixis Inc2.08bn466.92m10.24bn1.31k22.854.5020.704.921.571.576.927.960.70123.398.041,589,006.0015.738.8618.089.9196.2596.3022.4315.433.88--0.000.0013.6016.4713.98-21.343.98--
Tempus AI Inc640.44m-800.71m10.71bn2.30k--196.70--16.73-8.29-8.294.440.3459----------------53.18---116.06--2.55-14.950.891--65.85--20.35------
Sarepta Therapeutics Inc1.64bn121.85m10.92bn1.31k94.018.9468.046.661.221.2216.3012.790.4890.57034.351,248,362.003.63-21.634.38-25.7585.9286.657.43-77.053.03--0.5013--33.2632.8023.81--6.30--
Charles River Lbrtrs ntrntl Inc4.06bn413.08m11.04bn20.00k26.962.9214.382.728.018.0178.6373.970.52038.275.23203,045.805.486.466.337.6235.9336.9910.5411.581.144.960.37840.003.8612.75-2.3916.6917.86--
Medpace Holdings Inc2.07bn365.57m11.21bn5.90k31.5912.6928.445.4211.4211.4264.7028.421.16--6.85350,994.3020.4813.9443.5123.1829.6928.8417.6615.23----0.00--29.1721.7615.2631.1717.99--
BIO-TECHNE Corp1.17bn150.68m11.82bn3.10k79.155.5345.1210.090.94020.94027.2913.460.42672.155.47377,930.005.499.425.7710.0465.9367.2912.8621.413.2618.070.12322.791.9710.17-41.0711.8619.870.00
Vaxcyte Inc0.00-507.65m12.39bn254.00--3.62-----4.55-4.550.0027.470.00----0.00-20.08-34.22-20.95-37.21------------0.00-------80.00--107.28--
Data as of Nov 12 2024. Currency figures normalised to Exact Sciences Corp's reporting currency: US Dollar USD

Institutional shareholders

49.98%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Jun 202417.74m9.60%
Capital Research & Management Co. (World Investors)as of 30 Jun 202416.50m8.93%
Wellington Management Co. LLPas of 30 Sep 202414.65m7.93%
Fidelity Management & Research Co. LLCas of 30 Jun 202411.67m6.32%
SSgA Funds Management, Inc.as of 30 Jun 20248.21m4.44%
BlackRock Fund Advisorsas of 30 Jun 20247.50m4.06%
William Blair Investment Management LLCas of 30 Sep 20244.73m2.56%
Holocene Advisors, LPas of 30 Jun 20244.04m2.19%
Artisan Partners LPas of 30 Jun 20243.81m2.06%
JPMorgan Investment Management, Inc.as of 30 Sep 20243.48m1.89%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.